consequences, personal control, treatment control and illness identity all showed significant associations with quality of life (SF-36 domains) and disability (HAQ). Timeline scores were unrelated to HAQ or other outcome measures. Linear regression analyses (Table) showed IPQ-R scores for personal control and consequences had stronger associations with disability (HAQ) than clinical measures like DAS28. Overall, beliefs about illness identity, consequences and control explained 20% variance in HAQ scores and 24% variance in psychological functioning scores (SF-36 mental health summary score).
Conclusions: The medical model of care, focusing on treating RA inflammation, overlooks many potentially modifiable aspects of RA. There is a strong case for developing interventions that target beliefs, particularly those that enhance personal control and the ability to manage illness consequences. A cognitive behavioural approach that combines education, skills training and maintenance could achieve these goals. Disclosure: The authors have declared no conflicts of interest.
Linear Regression Analysis of Factors Influencing HAQ Scores (R2 ¼ 53%)
Assessment
Standardised Coefficients Significance Background: Objective: To assess the validity, reliability and comprehensibility of a developed low back pain (LBP) questionnaire for use in standard clinical care of patients suffering from LBP. Methods: The low back pain questionnaire was developed on a one-page sheet. One side includes 10 questions to stratify patients suffering from LBP according to their clinical presentation and whether their symptoms are secondary to local disorder or systemic disease. The other side includes: assessment of functional disability using, 4 items to assess psychological distress, duration of morning stiffness as well as visual analogue numerical scales for pain, patient global status, and fatigue. Consecutive patients suffering from LBP completed the questionnaire. Scores are entered in boxes on the right side of the page for each item. Clinical assessment for every patient was carried out. X-ray spine was requested for all patients. MRI scan for lower back were requested if the clinical presentation was suggestive of local disorder. Every patient completed also the Hamilton questionnaire for depression and anxiety. Blood check for full blood count, liver and kidney functions, lipid profile, immunology profile, thyroid functions, HbA1C, protein electrophoresis, inflammatory markers (ESR and CRP) were carried out for every patient. Test-retest reliability as well as comprehensibility of the model were also assessed. Results: 146 patients completed the questionnaire. The test was reliable as demonstrated by a high-standardized alpha value and minimal changes recorded in the 2nd from the 1st test. The HAQ-II (functional aspect) was significantly correlated with different parameters assessed giving an r-value higher than 0.5 with both patient global assessment, and pain score. The psychological aspect of the LBP questionnaire correlated significantly with fatigue score, pain score, and patient global assessment; the highest r-value was with fatigue score (0.815). The psychological score was significantly correlated with depression as well as anxiety scores as demonstrated by Hamilton scale for depression and anxiety (p < 0.001).
The LBP questionnaire showed also a high degree of comprehensibility (94.8%).
Conclusions:
The developed questionnaire is a reliable and valid instrument for assessment of patients suffering LBP. Being short, rapid and comprehensive, this adds more to its applicability. The data support the value of completion of the simple 2 page patient questionnaire, which provides a quantitative written documented record by the patients, at their visit to the rheumatology clinic. Disclosure: The authors have declared no conflicts of interest.
ANTI-TNF THERAPY WITH ADALIMUMAB FOR RADICULOPATHY PAIN OF SCIATICA, ABU DHABI EXPERIENCE
Mustafa Al Izzi and Eman Hussain Rheumatology, Mafraq Hospital, Abu Dhabi, United Arab Emirates Background: The favorable therapeutic outcomes of TNF alpha inhibition in the treatment of such disorders as rheumatoid arthritis, spondyloarthropathies and other systemic connective tissue diseases has now been extended into conditions in which the inflammatory process is localized as that found in patients with back pain and sciatica secondary to discogenic radiculopathy. There is a good evidence now from a number of studies that the exposed herniated nucleus pulposus can initiate a local inflammatory reaction at the level of the disc and adjacent nerve roots in which the secretion of TNF is abundant aggravating the '' radiculitis'' component of the sciatic pain even in the absence of demonstrable compression of the roots as evident by Magnetic Resonance Imaging (MRI) studies. Therapeutic interventions with the antiTNF agents in such patients have yielded variable results. Methods: A cohort of ten patients with back pain and sciatica attending our rheumatology clinic were selected for the study on the basis of:
1. severe radicular type of pain graded by the patient as grade 70 or greater on a visual analogue scale (VAS) of 0 -100 grade.
2. Chronic pain, occurring daily for at least 3 months and over. 3. Treatment resistance as evidenced by lack of response or partial response with relapse following disc surgery or epidural steroid injections.
All the 10 patients were given each (off-label) a subcutaneous injection of Adalimumab 40 mg which was repeated once only after 2 weeks.
Initial patients assessment included: history, physical examination with emphasis on straight leg raising (SLR) angle, plain spinal radiographs and spinal MRI.
Patients were assessed clinically regularly there after starting from the week 0 of the first injection then at week 2, 4 and week 8. Results: As a whole, all patients show some degree of improvement. The median leg pain VAS score reduction was 55. The median back pain VAS score reduction was 37. The median SLR angle improvement was 45. Conclusions: TNF inhibition with this fully human monoclonal antibody therapy Adalimumab has resulted in a moderate clinical improvement in the majority of this cohort of selected patients population with discogenic radicular sciatic pain. Though this study has its limitations, mainly the small number of patients sample which was due to logistic reasons related to supply of the medication, also the lack of a control group in which a placebo response might have been obtained. Never the less, the study results do high lighten the clinical utility of this form of therapy. Further wider scale studies are warranted to explore the full potentials of anti TNF agents therapy in this common disorder. Disclosure: The authors have declared no conflicts of interest.
TRANSDERMAL BUPRENORPHINE IN CLINICAL DAILY PRACTICE: EFFECTIVENESS AND TOLERABILITY IN PATIENTS SUFFERING FROM CHRONIC MUSCULOSKELETAL PAIN

Y. El Miedany and D. Palmer Rheumatology, Darent Valley Hospital, Kent, United Kingdom
Background: Buprenorphine, a potent opioid analgesic, has been available in parenteral, oral and sublingual formulations. Recently, the buprenorphine transdermal patches (TDS) were introduced for the treatment of chronic cancer and noncancer pain.
Objective: This study investigated the short-term effectiveness and tolerability of buprenorphine TDS for the relief of chronic musculoskeletal pain in routine clinical practice. Methods: This was a retrospective, observational, 1-month follow-up assessment of patients who were beginning buprenorphine TDS treatment for moderate to severe musculoskeletal pain that had not responded to analgesic therapy up to WHO step II opioids. Patches were to be changed every week. Patients' baseline scores before and 1-month after the treatment were recorded using a developed questionnaire. Pain relief was assessed using numeric VAS, and quality of life was assessed using the health assessment questionnaire II, psychological assessment were also carried out for sleep, depression as well as anxiety. Tolerability was determined based on adverse events recorded during the follow-up period. Results: The work included 84 patients, most of whom were outpatients. 64 (75%) of the cohort were women. The mean (SD) age was 65.7 (11.8) years. Regarding the cause of pain, 45.2% (38 patients) had chronic LBP, twenty (23.8%) patients had OA, 17 (20.2%) patients had osteoporotic pains, whereas 9 patients had neuropathic pain. 64 patients completed the 1-month follow-up period. There was a significant increase in the proportion of patients reporting very good or good pain relief as evidenced by the improvement in the pain score (p < 0.05). Quality of life also improved, baseline HAQ mean (SD) was 2.8 þ 0.46 score, and after 1-month it became 1.7 þ 0.31 (P < 0.01). Also there was significant improvement in the quality of sleep score (p < 0.01). 26 patients (40.6%) of the 64 patients experienced adverse events. The most common adverse events were nausea (15.4%), vomiting (11.5%), and constipation (11.5%); the most common local adverse events were pruritus (7.7%), dermatitis (7.7%), and erythema (3.8%). In 16/26 (61.5%), these side effects were managed medically and the patients continued their treatment course. More than half the patients (53.1%) asked to continue treatment with buprenorphine TDS. Conclusions: Buprenorphine TDS achieved a very good analgesic effect and was effective as well as tolerated overall. It may prove particularly useful in patients who have experienced side effects taking oral analgesic preparations, as well as in those who are taking extensive co-medications. Disclosure: The authors have declared no conflicts of interest.
THE DESIGN AND DEVELOPMENT OF A VALIDATED, REPRODUCIBLE SCORING SYSTEM FOR PATELLAR TENDINOPATHY USING POWER DOPPLER ULTRASONOGRAPHY
Sandeep Bawa, Eugene McNally and Julia Newton
Rheumatology, Nuffield Orthopaedic Centre, Oxford, United Kingdom Background: Patellar tendinopathy(PT) is a significant cause of pain and disability in athletes. PT can be a significant factor in prematurely ending professional athletes' careers. The ultrasound appearances are well described. The presence and severity of neovascularisation is a potential prognostic tool in determining the severity of PT. Currently no validated scoring system exists for neovascularisation using power Doppler ultrasonography (PDUSS). The development of a validated and reproducible scoring system would be an invaluable research tool. A score that correlates with clinical severity will allow more targeted treatment strategies and a reduction in the time to return to painfree sporting activity.
The primary objective was to propose a validated scoring system to quantify neovascularisation in athletes with PT using PDUSS. Secondary objectives were to identify any correlation between:
1. The severity of neovascularisation and the VISA score.
2. The severity of neovascularisation and the area of tendinopathy.
3. The area of tendinopathy and the VISA score. Methods: Approval was granted from the institutional clinical effectiveness and audit committee. 6 athletes with a clinical diagnosis of PT were recruited prospectively from the sports medicine clinic. At initial consultation athletes filled out the VISA questionnaire. Patients were then subject to ultrasonography (gray scale and PDUSS). A grading system was devised on a 0-3 scale to quantify neovascularisation on ultrasonography. Standardised sonographic images were taken and stored in both axial and sagittal views. This enabled the evaluation of inter and intra observer reproducibility of the scoring system. Pearson's correlation coefficient, linear regression and the t test was used in the statistical analysis. Results: The proposed scoring system demonstrated excellent inter (r > 0.89, p ¼ 0.36) and intra (r ¼ 1) observer reproducibility thus validating the method used. There was a strong negative correlation seen between neovascularisation and the VISA score (r ¼ À0.83) demonstrating clinical relevance. There was poor correlation between the area of tendinopathy and neovascularisation (r ¼ 0.69). There was a strong negative correlation seen between the area of tendinopathy and the VISA score (r ¼ À0.98).
Conclusions:
We propose the first validated scoring system for quantifying neovascularisation in athletes with PT using PDUSS. This new ultrasound severity index (OPTUS -Oxford Patellar Tendinopathy Ultrasound Score) has clear clinical relevance demonstrated by the strong correlation with the VISA score. This should be used as a measure of severity in future longitudinal studies to assess clinical outcome. If successfully proven to be a prognostic marker, it could lead to more targeted management strategies and a reduction in morbidity seen in elite athletes. Disclosure: The authors have declared no conflicts of interest.
GUIDELINES FOR REFERRERS ON THE RATIONAL USE OF LIMITED EMG SERVICE IN A DISTRICT GENERAL HOSPITAL
C. Solymossy, R. Ariyaratnam, J. Greenwood, T. Hammad and F. Jepson Rheumatology, ELHT, Burnley, United Kingdom Background: Carpal Tunnel Syndrome (CTS) is the most common entrapment neuropathy with electrophysiologically confirmed CTS being estimated at 3% in women and 2% in men, with the peak prevalence in women aged over 55(1); it has lately gained notice as one of the more commonly reported occupational illnesses(1).
Since 1995 we have provided a limited electromyography (EMG) service for the local population. The waiting time for this investigation grew from 6 weeks in 1995 to more than 6 months in 2002. The most likely reasons for this are increased awareness of the condition among the public and GPs, and some Orthopaedic Surgeons are hesitant to operate without EMG confirmation. AIM EMG referrals for suspected CTS between September 2002 and September 2003 were retrospectively analysed with a view to producing Guidelines for the rational use of the service by referrers. Methods: The following data was obtained from the hospital medical records: Patient demographics, referrers, contributing factors, presenting complaints, clinical findings, EMG results, treatment given and the response to treatment. Results: Of 152 referrals for suspected CTS, 30% were males and 70% females.50% were aged 50-75,37% aged 25-50 and 13% were >75 yrs.
Clinical presentation: 25% had symptoms only, 59% had symptoms and sensory signs, 5% had symptoms and motor signs;there was no documentation in the other 11%.
Contributing factors: 7.3% had hypothyroidism, 6.6% had diabetes, 15.1% had osteoarthritis,16.4% were obese, 2.6% had rheumatoid arthritis and 2.6% were post-traumatic. Conclusions: Most EMG referrals came from GPs(41.4%) and Orthopaedic surgeons(40.1%).
24.3% EMGs were normal and 38.2% mild; these patients (62.5%) could have been managed conservatively without the need for EMG.
16/26(61.5%) patients responded well to the use of splints We produced the following evidence-based guidelines for the referrers to use in patients suspected of CTS and have passed these guidelines on to our referrers and hope to audit the referrals next year. Disclosure: The authors have declared no conflicts of interest. 
GLUCOCORTICOID INJECTIONS IN LESIONS OF THE ACHILLES TENDON -A SYSTEMATIC REVIEW
David Metcalfe Warwick Medical School, University of Warwick, Coventry, United Kingdom
Background: Achilles tendinopathy describes the presence of one or more pathological lesions in the Achilles tendon or surrounding tissues. These lesions are associated with overuse of the tendon, particularly in older male athletes involved in running and jumping. A number of non-surgical interventions are used to manage Achilles tendinopathy. In particular, local glucocorticoid injections have generated controversy in recent years. Although a number of case reports indicate symptomatic relief following glucocorticoid injection, one systematic review found little evidence to support their efficacy. Furthermore, some evidence associates local glucocorticoid injections with rupture of the Achilles tendon. Nevertheless, authors continue to publish cases suggesting a role for peritendinous and even intratendinous glucocorticoid injections in Achilles tendinopathy. This systematic review appraised the available literature to evaluate the efficacy of local glucocorticoid injections in lesions of the Achilles tendon. Methods: The search strategy encompassed five databases, namely Medline, EMBASE, CINAHL, AMED and the Cochrane Library. All interventional and observational studies were included and review articles were analysed for further sources. Only studies reporting the outcome of at least one injection for Achilles tendinopathy were included. TREATMENT 
Results: A total of 187 articles were identified, only five of which met the inclusion criteria. These included one randomised controlled trial, three retrospective studies, and one prospective case series. The only randomised controlled trial available studied only 28 patients. Although these authors found against glucocorticoid injections, they did not follow up eight patients leaving the trial prematurely. Given the small sample size, eight patients leaving the trial because of improved or worsening pain might have introduced a significant selection bias. Indeed, a number of retrospective studies have found symptomatic improvement following peritendinous injection. However, these studies often suffer from small sample size, absence of a suitable control, and selection biases. Despite these limitations, all three studies reported symptomatic relief and no increased risk of tendon rupture post-injection. One small case series (5 patients) even reported reduced tendon pain following intratendinous injection. Conclusions: There is not yet an emerging consensus as to whether local glucocorticoid injections have a therapeutic role in lesions of the Achilles tendon. Although the only clinical trial found against glucocorticoid injections, more recent studies have shown steroids to offer symptomatic relief in Achilles tendon lesions. Further research is required to improve our understanding of tendon pathology and the effect of glucocorticoids on soft tissues before any firm conclusion may be drawn about their use in Achilles tendinopathy. Disclosure: The author has declared no conflicts of interest. Background: Chronic widespread pain (CWP) is associated with an increased risk of mortality, primarily from cancer and cardiovascular deaths. Several mechanisms may explain this relationship; one such mechanism is that CWP is associated with low levels of physical activity (PA), which over time are associated with an increased risk of mortality. The aim of this study was to test the hypothesis that CWP would predict low levels of PA. Methods: A population-based prospective study recruited subjects aged 25-65 years from 3 general practices in North West England. Pain status and PA levels were ascertained at baseline and 32 months later using a postal survey. PA was measured using 3 questions: ''in comparison with others your own age, do you think your PA is ''the same'' (referent group), ''more-much more'' or ''less-much less'''', and ''during the past month on average how many days per week have you taken exercise that has i) lasted at least 20 minutes? and ii) made you sweat? ''4-7'' (referent), ''1-3'' or ''none''''. Baseline data on potential confounding factors, including psychosocial status, demographic and lifestyle factors, was also collected. Multinomial logistic regression models were used to assess the relationship between baseline CWP and each of the PA questions at follow-up, adjusted for age and gender. Results are presented as relative risk ratios (RRR) with 95% confidence intervals (95% CI). Results: Of 3241 eligible subjects, 2499 (77%) participated at both timepoints, of whom 2419 provided complete pain and PA information. CWP was reported by 18% (n ¼ 429) of participants at baseline, these subjects were more likely to be female (p ¼ 0.02) and older (p < 0.01) than those free of CWP. Compared to subjects who were free of CWP at baseline, those with CWP had an increased risk of reporting ''less-much less'' PA at follow-up (RRR ¼ 3.1; 95% CI: 2.4-4.1). This relationship remained after adjustment for potential confounders and was not fully explained by baseline levels of PA (RRR ¼ 1.9; 95% CI: 1.4-2.5). However, there was no relationship observed between baseline CWP status and subjects who reported ''none'' compared to ''4-7'' for the average number of days per week participated in exercise at follow-up that i) lasted at least 20 minutes (RRR ¼ 1.3; 95% CI: 0.9-1.7) or ii) caused sweating (RRR ¼ 1.01; 95% CI: 0.7-1.5).
Conclusions:
The current study demonstrates that low self-reported levels of PA are a consequence of having CWP. Objective measurements of PA, in future studies, will determine whether such changes could account for increased mortality. Background: Joint hypermobility is commonly diagnosed in children with musculoskeletal (MSK) complaints. It is established that joint hypermobility significantly contributes to MSK complaints in adult rheumatological practice as well. About 5% of the Caucasian population are thought to have hypermobility and many have either limb-specific or widespread musculoskeletal pain. We have assessed the prevalence of benign joint hypermobility syndrome (BJHS) in our adult rheumatology clinics.
Methods:
We identified all patients in Gateshead who attended one author's (VS) new patient clinic for one month. We reviewed their case-notes to confirm the diagnosis using standard criteria for the confirmation of BJHS, including Beightons score, large and small joint range of movement, spinal movement and other features such as skin striae where relevant. We recorded any suspicion of hypermobility in the refferal letter together with reasons for referral. Results: We identified 67 patients who attended in the month of February 2007. Inflammatory arthritis was diagnosed in 19 and the remaining 48 patients were found to have non-inflammatory MSK diseases. The break down of diagnoses is given in the Table, which confirms a diagnosis of BJHS in 7 patients. Several diagnoses sometimes co-existed. The referral letter only mentioned hypermobility in 2 cases and in 5 cases patients with BJHS had been labelled as having a chronic pain syndrome. Conclusions: We have shown that BJHS is present in 15% patients with noninflammatory MSK diseases, and in 10% of new adult rheumatology referrals overall. There may be a lack of awareness among primary care practitioners as hypermobility was only rarely mentioned in the GP referral letter. Many patients with BJHS had been diagnosed as having chronic pain syndromes, fibromyalgia, inflammatory arthritis etc. and this may be associated with poorer outcome due to misdiagnosis. Greater recognition of the presentation and management of BJHS is needed across the spectrum of primary and secondary care. Disclosure: The authors have declared no conflicts of interest. Background: Chronic widespread pain (CWP) is common in the general population and is considered to be largely unexplained by organic causes. Whether this is true is unclear. Aim: To determine the prevalence of CWP that is unexplained by organic causes in the general population. Methods: We conducted a population based postal survey in two general practices in the North West of England. The questionnaire asked about any pain respondents had experienced for one day or longer in the past month. Additional questions asked about pain duration. Based upon their questionnaire responses those respondents satisfying the American College of Rheumatology criteria for CWP were identified. We sought consent to review medical records held at the general practice. Two doctors independently rated the medical records of all those with CWP for the 12 months prior to and after the date of questionnaire completion. We identified those who had consulted and, if so, whether an organic cause was recorded that could explain the presence of CWP at the time of questionnaire completion. Respondents were classified into ''organic'' (symptoms were likely to have an organic cause) and ''unexplained'' (no evidence of organic cause) CWP. Results: 2985 people were mailed a questionnaire and 1601 responded (response rate 64.3% after removing from the denominator the 496 who had moved or died before the study had started Background: An increased prevalence of musculoskeletal disease is recognised in diabetes and is a common source of disability. Its relationship to complications of diabetes is poorly understood and its correlation with diabetic control is unknown. Furthermore, there is little data on the differences between types 1 and 2 diabetes with regard to musculoskeletal disease. Methods: We identified a group of 45 out patients with established type 1 diabetes and matched them for both gender and duration of disease with a group of 51 type 2 out patient diabetics. We examined them for the presence of locomotor disease using the GALS screening test followed by a more detailed regional examination (REMS) of the upper limbs. The presence of all abnormalities were recorded and the specific nature of upper limb abnormalities was carefully defined. The average HbA1c over the previous year was noted as was the presence of diabetic retinopathy or neuropathy. The mean HAQ was recorded and correlations between the presence of locomotor disease and HbA1c, other diabetic complications and HAQ were calculated. We compared data between the two groups of diabetics and contrasted the amalgamated data with that of unselected medical out patients.
Breakdown of diagnoses of non-inflammatory MSK diseases
Results: 63% of our patients were male and the group had a median age of 55 years with median duration of diabetes of 13 years. GALS revealed evidence of locomotor disease in 75% with the upper limb the commonest site for abnormalities. Shoulder capsulitis (25%), carpal tunnel syndrome (19%), cheirarthropathy (28%) and Dupuytrens (19%) were the most frequent findings. Capsulitis usually coexisted with other upper limb abnormalities and best predicted the presence of retinopathy and/or neuropathy. The mean HbA1c was significantly higher in patients with combined shoulder and hand problems (9.1) than in those with no upper limb problems (8.0) [p ¼ 0.018]. The pattern of results was very similar in type 1 and type 2 diabetics, although the prevalence of abnormalities and mean HAQ were considerably higher in type 2 patients, with significantly more disability resulting.
Conclusions: Upper limb locomotor abnormalities are very common in diabetes and associate with both worse diabetic control and other diabetic complications. Type 1 diabetics have a lower prevalence and less resulting disability than type 2 diabetics even when matched for gender, duration of disease and diabetic control. Background: In 2002 we established a cohort of ballet dancers, identifying degrees of hypermobility and prevalence of Joint Hypermobility Syndrome (JHS) (1). In females 34% had a phenotype of JHS, excluding musculoskeletal symptoms as criteria. The prevalence fell with seniority. Pain was reported in 55% of females and more often by those with JHS. Among males, 35% had JHS. Pain was not associated with JHS but reporting was generally high at 80%. We suggested JHS may be associated with risk of injury, particularly in females, and that this may have a negative effect on training. The current study is a 5-year follow-up of the cohort. Since 2002 there have been no training interventions aimed specifically at preventing injury in dancers with JHS that we are aware of. Methods: A self-assessment questionnaire was sent to the cohort. Questions related to symptoms/conditions over the last 5 years, and the frequency of occurrance e.g. spinal pain, ankle sprains, tendon and ligament injuries. We also asked about prolonged periods of time off from dancing due to injury, and whether this occured on more than one occasion. Odds ratios were calculated for the presence of JHS and injury.
Results: Of ninety-three dancers(69% response rate), 50 were still with the Royal Ballet Company, 43 elsewhere, with 55 females and 38 males. The prevalence of JHS was 33% for females and 32% for males; figures in keeping with those found at baseline in 2002, suggesting little response bias. In both sexes no significant difference was seen between JHS and non-JHS dancers in the reporting of multiple joint pain, cervical/dorsal/lumbar pain, dislocations, ankle or shoulder injury, or fracture. A significantly higher reporting of ligament injuries and periods of >6 weeks off dancing was reported by those with JHS (Table 1) . Conclusions: Dancers with JHS are more likely to report prolonged time off, the possible causes being more severe injury or longer healing time. Slower training, emphasis on proprioception, safe biomechanics, and understanding prolonged healing times, might facilitate better outcome in these dancers. Background: Vitamin D is recognised as an important contributor to musculoskeletal health and immunity. A lack of vitamin D has been shown to act as a contributing factor to various cancers, diabetes mellitus, multiple sclerosis and rheumatoid arthritis [1] .Lower vitamin D levels have also been found in fibromyalgic patients compared to controls. We asked the question whether patients with inflammatory arthritis or fibromyalgia had lower levels of vitamin D compared to all other patients presenting with general rheumatological conditions. Methods: As part of a Trust audit, all rheumatology patients' vitamin D levels were obtained from April 2006 to March 2007. Demographic data was collected including age, diagnosis and current treatments. Conditions were categorised into 3 groups:
(1) general rheumatology (including soft tissue, degenerative, connective tissue disease, polymyalgia rheumatica); (2) inflammatory arthritis; (3) chronic widespread unexplained pain. The results were compared using the Kruskal-Wallis nonparametric test and seasonally adjusted Z scores generated compared to the East Anglian Healthy reference range for older adults.
Results: 144 patients were identified and summarised in Table 1 . There were only minor baseline imbalances in age,gender and current vitamin D treatment between the groups.Mean Z score of vitamin D was -1.3 versus healthy older adults. There were significant differences between the levels of vitamin D between the general rheumatology and inflammatory arthritis group as well between the general rheumatology and chronic unexplained pain.
Conclusions: This retrospective analysis represents a pragmatic approach to answering the posed question. There are significantly lower levels of vitamin D in patients presenting to secondary care rheumatology service who have a diagnosis of inflammatory arthritis and chronic widespread pain. Numbers are small in this pragmatic retrospective analysis and confounders have not been adequately controlled but this observation supports previous studies and hypotheses and requires further investigation. Disclosure: The authors have declared no conflicts of interest. 1. Holick ME. Am J Clin Nutr,2004;79:362-71. All subjects were invited to attend for further assessment which included an interviewer assisted questionnaire examining levels of physical activity (Physical Activity Scale in the Elderly) and mood (Beck Depression Inventory) and height and weight was measured. A fasting blood sample was taken for assessment of insulin like growth factor (IGF)-1, IGF binding protein (IGFBP)-1 and IGFBP-3. Logistic regression was used to determine the association between these variables and CWP, with the results expressed as odds ratios (OR) and 95% confidence intervals (CI).
Results: A total of 3,369 men, mean age 60 (SD ¼ 11) years provided data for this analysis. Of those 278 (8.7%) reported CWP. IGF-1 levels were similar among those with and without CWP: 133.5 mg/L vs 129.1 mg/L respectively. This was true also for IGFBP-1 (2.82 vs 2.71) and IGFBP-3 (4.43 vs 4.34). A higher body mass index, lower levels of physical activity, and a higher depression score were significantly associated with CWP. In regression analysis, after adjusting for centre, IGF1 levels (per unit increase in IGF1 level, OR ¼ 1.00; 95%CI 1.00, 1.00), IGFBP1 (OR ¼ 1.00; 95% CI 0.97, 1.02) and IGFBP3 (OR ¼ 0.95; 95% 0.84, 1.07) were not associated with CWP. The results were not affected by further adjustment for age, body mass index, physical activity and depression score. Conclusions: Our data do not support an association between growth hormone axis function and the occurrence of CWP in men. Background: Chronic widespread pain (CWP) is common in the general population and is associated with other functional disorders (irritable bowel syndrome (IBS), oro-facial pain (OFP) and chronic fatigue (CF)) and high levels of psychological distress. There is a common perception that the prevalence CWP is low in elderly populations however data is limited. The aims of the study were to determine the prevalence and associated factors of CWP in an ageing population. Methods: Participants (N ¼ 827) in a long-term prospective cohort study of ageing in the North of England completed a postal questionnaire. The questionnaire included items about the occurrence and duration of pain. Four line drawings (blank body manikins: front, back and sides) accompanied the pain questions and subjects were asked to indicate the site(s) of any pain they had experienced for one day or longer in the past month. Subjects who satisfied ACR criteria for CWP were identified. The questionnaire also contained validated measures of OFP (Manchester Scale), IBS (Rome II criteria) and CF (The Fatigue Scale). Depression and anxiety were measured using the Cornell Medical Index. Logistic regression was used to examine the associations between CWP, and psychological distress and multiple symptom reporting with the results expressed as odds ratios (OR) and 95% confidence intervals (95% CI).
Results: A total of 734 (89% response rate) returned the completed questionnaire. Of those 555 (75%) were female and the median age was 81.0 years (range ¼ 68-98 years). The prevalence of CWP was 14.6% (N ¼ 107). Significantly more females than males reported symptoms (N ¼ 90, 16.4% vs. N ¼ 15, 8.6%; p ¼ 0.01) although there was no significant difference in age between CWP and CWP free subjects (Mann-Whitney U, p ¼ 0.17). Logistic regression revealed that, compared to those free of CWP, individuals with CWP were more likely to report high levels of depression (OR ¼ 1.9, 95% CI (1.2-3.2)) and anxiety (OR ¼ 2.4, 95% CI (1.5-3.9)). The prevalence of CF was 11.2% (N ¼ 79), while 2.4% (N ¼ 17) reported chronic OFP and 2.7% (N ¼ 19) reported IBS. Logistic regression revealed that, compared to those free of CWP, individuals with CWP were 4 times more likely (OR ¼ 4.3, 95% CI (2.6-7.3)) to report one or more additional functional disorders.
Conclusions: Contrary to anecdotal evidence, CWP is common in elderly populations and is associated with other symptoms and markers of psychological distress. Disclosure: The authors have declared no conflicts of interest.
